Relief Therapeutics is a publicly-traded drug development company focusing primarily on the clinical development of peptides and proteins of natural or engineered origin. They produce and commercialize atexakin alfa, for the treatment of neuropathies. The company currently focuses on diabetic complications and respiratory diseases.

Relief Therapeutics was founded in 2013 and is headquartered in Switzerland.